Cardio Diagnostics Holdings, Inc.CDIO

NasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances
Price (close)
$1.95
Market cap
$5.8M
P/E
—
Revenue (TTM)
$14,450
Net income
-$6.5M
Dividend yield
—
1-year total return
-52.0%
Net margin
-44771.8%
Revenue growth
-25.9%
Debt / equity
—

What Cardio Diagnostics Holdings, Inc. does.

a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (“CHD”),

stroke, heart failure and diabetes, by leveraging our Artificial Intelligence (“AI”)-driven Multi-Omics Engine™ (formerly

company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases. Cardio aims to become

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue—$901$950$17,065$34,890$14,825
Net income—-$620,448-$4.7M-$8.4M-$8.4M-$6.5M
Free cash flow———-$6.2M-$5.2M-$5.9M

More on CDIO.

Figures from Cardio Diagnostics Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.